World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation
Pulmonary hypertension associated with left heart disease is the most common form of pulmonary hypertension encountered in clinical practice today. Although frequently a target of therapy, its pathophysiology remains poorly understood and its treatment remains undefined. Pulmonary hypertension in th...
Gespeichert in:
| Veröffentlicht in: | The Journal of heart and lung transplantation 2012-09, Vol.31 (9), p.913-933 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 933 |
|---|---|
| container_issue | 9 |
| container_start_page | 913 |
| container_title | The Journal of heart and lung transplantation |
| container_volume | 31 |
| creator | Fang, James C., MD DeMarco, Teresa, MD Givertz, Michael M., MD Borlaug, Barry A., MD Lewis, Gregory D., MD Rame, J. Eduardo, MD, Mphil Gomberg-Maitland, Mardi, MD, MSc Murali, Srinivas, MD Frantz, Robert P., MD McGlothlin, Dana, MD Horn, Evelyn M., MD Benza, Raymond L., MD |
| description | Pulmonary hypertension associated with left heart disease is the most common form of pulmonary hypertension encountered in clinical practice today. Although frequently a target of therapy, its pathophysiology remains poorly understood and its treatment remains undefined. Pulmonary hypertension in the context of left heart disease is a marker of worse prognosis and disease severity, but whether its primary treatment is beneficial or harmful is unknown. An important step to the future study of this important clinical problem will be to standardize definitions across disciplines to facilitate an evidence base that is interpretable and applicable to clinical practice. In this current statement, we provide an extensive review and interpretation of the current available literature to guide current practice and future investigation. At the request of the Pulmonary Hypertension (PH) Council of the International Society for Heart and Lung Transplantation (ISHLT), a writing group was assembled and tasked to put forth this document as described above. The review process was facilitated through the peer review process of the Journal of Heart and Lung Transplantation and ultimately endorsed by the leadership of the ISHLT PH Council. |
| doi_str_mv | 10.1016/j.healun.2012.06.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1033453307</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1053249812011242</els_id><sourcerecordid>1033453307</sourcerecordid><originalsourceid>FETCH-LOGICAL-c559t-d929a88cbbca2bf1fd900ab6d0fa9f0dba7e46d2c5cb7fe0f237297e6ba8cae93</originalsourceid><addsrcrecordid>eNqFks2KFDEQxxtR3HX0DURyEbzMmE7604OwDLqzMLDCrngM6aSykzGdjPkQxpMP4RP6Dt5Nz6y6COIpIfWr-lfVP0XxtMSLEpfNy-1iA9wkuyC4JAvcLDAm94rTsq7bOS3L9n6-45rOSdV3J8WjELY4E7QmD4sTQrquoh0-LX58cN5ItMql4gZd-htu9RcetbPoXTKjs9zv0Wq_Ax_Bhun53Lu0Q-TVnfjmblwmQNEhAyqi3KGPSOoAPADSFsUNIC6Tid-_fuMopHGc8kPkEUawESnvxgP0D_GlS1Zog5w6UBc2greHdrlBV05oiHuknJ8GysrcSrRO9gZde27DznAbD_Dj4oHiJsCT23NWvH_75nq5mq8vzy-WZ-u5qOs-zmVPet51YhgEJ4Mqlewx5kMjseK9wnLgLVSNJKIWQ6sAK0Jb0rfQDLwTHHo6K14c6-68-5QgRDbqIMDkRsClwEpMaVVTituMVkdUeBeCB8V2Xk_byRCbDGdbdjScTYYz3LDJzlnx7FYhDSPI30m_HM7A81uAB8GNyosQOvzhmrpvaU8z9_rIQd7HZw2ehbxNK0BqDyIy6fT_Ovm7gDDa6qz5EfYQti5lp0yemYWcw66mzzn9zTIXKUlF6E_ySOnS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1033453307</pqid></control><display><type>article</type><title>World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Fang, James C., MD ; DeMarco, Teresa, MD ; Givertz, Michael M., MD ; Borlaug, Barry A., MD ; Lewis, Gregory D., MD ; Rame, J. Eduardo, MD, Mphil ; Gomberg-Maitland, Mardi, MD, MSc ; Murali, Srinivas, MD ; Frantz, Robert P., MD ; McGlothlin, Dana, MD ; Horn, Evelyn M., MD ; Benza, Raymond L., MD</creator><creatorcontrib>Fang, James C., MD ; DeMarco, Teresa, MD ; Givertz, Michael M., MD ; Borlaug, Barry A., MD ; Lewis, Gregory D., MD ; Rame, J. Eduardo, MD, Mphil ; Gomberg-Maitland, Mardi, MD, MSc ; Murali, Srinivas, MD ; Frantz, Robert P., MD ; McGlothlin, Dana, MD ; Horn, Evelyn M., MD ; Benza, Raymond L., MD</creatorcontrib><description>Pulmonary hypertension associated with left heart disease is the most common form of pulmonary hypertension encountered in clinical practice today. Although frequently a target of therapy, its pathophysiology remains poorly understood and its treatment remains undefined. Pulmonary hypertension in the context of left heart disease is a marker of worse prognosis and disease severity, but whether its primary treatment is beneficial or harmful is unknown. An important step to the future study of this important clinical problem will be to standardize definitions across disciplines to facilitate an evidence base that is interpretable and applicable to clinical practice. In this current statement, we provide an extensive review and interpretation of the current available literature to guide current practice and future investigation. At the request of the Pulmonary Hypertension (PH) Council of the International Society for Heart and Lung Transplantation (ISHLT), a writing group was assembled and tasked to put forth this document as described above. The review process was facilitated through the peer review process of the Journal of Heart and Lung Transplantation and ultimately endorsed by the leadership of the ISHLT PH Council.</description><identifier>ISSN: 1053-2498</identifier><identifier>EISSN: 1557-3117</identifier><identifier>DOI: 10.1016/j.healun.2012.06.002</identifier><identifier>PMID: 22884380</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Biological and medical sciences ; Cardiology. Vascular system ; Endothelin Receptor Antagonists ; Heart Diseases - complications ; heart failure ; heart transplant ; Heart-Assist Devices ; Humans ; Hypertension, Pulmonary - diagnosis ; Hypertension, Pulmonary - etiology ; Hypertension, Pulmonary - physiopathology ; Hypertension, Pulmonary - therapy ; left heart disease ; left ventricular assist device ; Medical sciences ; Mitral Valve Insufficiency - complications ; Mitral Valve Stenosis - complications ; Phosphodiesterase Inhibitors - therapeutic use ; Pneumology ; pulmonary hypertension ; Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases ; right heart failure ; Surgery ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the heart ; Vasodilator Agents - therapeutic use</subject><ispartof>The Journal of heart and lung transplantation, 2012-09, Vol.31 (9), p.913-933</ispartof><rights>International Society for Heart and Lung Transplantation</rights><rights>2012 International Society for Heart and Lung Transplantation</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2012 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c559t-d929a88cbbca2bf1fd900ab6d0fa9f0dba7e46d2c5cb7fe0f237297e6ba8cae93</citedby><cites>FETCH-LOGICAL-c559t-d929a88cbbca2bf1fd900ab6d0fa9f0dba7e46d2c5cb7fe0f237297e6ba8cae93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1053249812011242$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26597393$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22884380$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fang, James C., MD</creatorcontrib><creatorcontrib>DeMarco, Teresa, MD</creatorcontrib><creatorcontrib>Givertz, Michael M., MD</creatorcontrib><creatorcontrib>Borlaug, Barry A., MD</creatorcontrib><creatorcontrib>Lewis, Gregory D., MD</creatorcontrib><creatorcontrib>Rame, J. Eduardo, MD, Mphil</creatorcontrib><creatorcontrib>Gomberg-Maitland, Mardi, MD, MSc</creatorcontrib><creatorcontrib>Murali, Srinivas, MD</creatorcontrib><creatorcontrib>Frantz, Robert P., MD</creatorcontrib><creatorcontrib>McGlothlin, Dana, MD</creatorcontrib><creatorcontrib>Horn, Evelyn M., MD</creatorcontrib><creatorcontrib>Benza, Raymond L., MD</creatorcontrib><title>World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation</title><title>The Journal of heart and lung transplantation</title><addtitle>J Heart Lung Transplant</addtitle><description>Pulmonary hypertension associated with left heart disease is the most common form of pulmonary hypertension encountered in clinical practice today. Although frequently a target of therapy, its pathophysiology remains poorly understood and its treatment remains undefined. Pulmonary hypertension in the context of left heart disease is a marker of worse prognosis and disease severity, but whether its primary treatment is beneficial or harmful is unknown. An important step to the future study of this important clinical problem will be to standardize definitions across disciplines to facilitate an evidence base that is interpretable and applicable to clinical practice. In this current statement, we provide an extensive review and interpretation of the current available literature to guide current practice and future investigation. At the request of the Pulmonary Hypertension (PH) Council of the International Society for Heart and Lung Transplantation (ISHLT), a writing group was assembled and tasked to put forth this document as described above. The review process was facilitated through the peer review process of the Journal of Heart and Lung Transplantation and ultimately endorsed by the leadership of the ISHLT PH Council.</description><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Endothelin Receptor Antagonists</subject><subject>Heart Diseases - complications</subject><subject>heart failure</subject><subject>heart transplant</subject><subject>Heart-Assist Devices</subject><subject>Humans</subject><subject>Hypertension, Pulmonary - diagnosis</subject><subject>Hypertension, Pulmonary - etiology</subject><subject>Hypertension, Pulmonary - physiopathology</subject><subject>Hypertension, Pulmonary - therapy</subject><subject>left heart disease</subject><subject>left ventricular assist device</subject><subject>Medical sciences</subject><subject>Mitral Valve Insufficiency - complications</subject><subject>Mitral Valve Stenosis - complications</subject><subject>Phosphodiesterase Inhibitors - therapeutic use</subject><subject>Pneumology</subject><subject>pulmonary hypertension</subject><subject>Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases</subject><subject>right heart failure</subject><subject>Surgery</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the heart</subject><subject>Vasodilator Agents - therapeutic use</subject><issn>1053-2498</issn><issn>1557-3117</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFks2KFDEQxxtR3HX0DURyEbzMmE7604OwDLqzMLDCrngM6aSykzGdjPkQxpMP4RP6Dt5Nz6y6COIpIfWr-lfVP0XxtMSLEpfNy-1iA9wkuyC4JAvcLDAm94rTsq7bOS3L9n6-45rOSdV3J8WjELY4E7QmD4sTQrquoh0-LX58cN5ItMql4gZd-htu9RcetbPoXTKjs9zv0Wq_Ax_Bhun53Lu0Q-TVnfjmblwmQNEhAyqi3KGPSOoAPADSFsUNIC6Tid-_fuMopHGc8kPkEUawESnvxgP0D_GlS1Zog5w6UBc2greHdrlBV05oiHuknJ8GysrcSrRO9gZde27DznAbD_Dj4oHiJsCT23NWvH_75nq5mq8vzy-WZ-u5qOs-zmVPet51YhgEJ4Mqlewx5kMjseK9wnLgLVSNJKIWQ6sAK0Jb0rfQDLwTHHo6K14c6-68-5QgRDbqIMDkRsClwEpMaVVTituMVkdUeBeCB8V2Xk_byRCbDGdbdjScTYYz3LDJzlnx7FYhDSPI30m_HM7A81uAB8GNyosQOvzhmrpvaU8z9_rIQd7HZw2ehbxNK0BqDyIy6fT_Ovm7gDDa6qz5EfYQti5lp0yemYWcw66mzzn9zTIXKUlF6E_ySOnS</recordid><startdate>20120901</startdate><enddate>20120901</enddate><creator>Fang, James C., MD</creator><creator>DeMarco, Teresa, MD</creator><creator>Givertz, Michael M., MD</creator><creator>Borlaug, Barry A., MD</creator><creator>Lewis, Gregory D., MD</creator><creator>Rame, J. Eduardo, MD, Mphil</creator><creator>Gomberg-Maitland, Mardi, MD, MSc</creator><creator>Murali, Srinivas, MD</creator><creator>Frantz, Robert P., MD</creator><creator>McGlothlin, Dana, MD</creator><creator>Horn, Evelyn M., MD</creator><creator>Benza, Raymond L., MD</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120901</creationdate><title>World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation</title><author>Fang, James C., MD ; DeMarco, Teresa, MD ; Givertz, Michael M., MD ; Borlaug, Barry A., MD ; Lewis, Gregory D., MD ; Rame, J. Eduardo, MD, Mphil ; Gomberg-Maitland, Mardi, MD, MSc ; Murali, Srinivas, MD ; Frantz, Robert P., MD ; McGlothlin, Dana, MD ; Horn, Evelyn M., MD ; Benza, Raymond L., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c559t-d929a88cbbca2bf1fd900ab6d0fa9f0dba7e46d2c5cb7fe0f237297e6ba8cae93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Endothelin Receptor Antagonists</topic><topic>Heart Diseases - complications</topic><topic>heart failure</topic><topic>heart transplant</topic><topic>Heart-Assist Devices</topic><topic>Humans</topic><topic>Hypertension, Pulmonary - diagnosis</topic><topic>Hypertension, Pulmonary - etiology</topic><topic>Hypertension, Pulmonary - physiopathology</topic><topic>Hypertension, Pulmonary - therapy</topic><topic>left heart disease</topic><topic>left ventricular assist device</topic><topic>Medical sciences</topic><topic>Mitral Valve Insufficiency - complications</topic><topic>Mitral Valve Stenosis - complications</topic><topic>Phosphodiesterase Inhibitors - therapeutic use</topic><topic>Pneumology</topic><topic>pulmonary hypertension</topic><topic>Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases</topic><topic>right heart failure</topic><topic>Surgery</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the heart</topic><topic>Vasodilator Agents - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fang, James C., MD</creatorcontrib><creatorcontrib>DeMarco, Teresa, MD</creatorcontrib><creatorcontrib>Givertz, Michael M., MD</creatorcontrib><creatorcontrib>Borlaug, Barry A., MD</creatorcontrib><creatorcontrib>Lewis, Gregory D., MD</creatorcontrib><creatorcontrib>Rame, J. Eduardo, MD, Mphil</creatorcontrib><creatorcontrib>Gomberg-Maitland, Mardi, MD, MSc</creatorcontrib><creatorcontrib>Murali, Srinivas, MD</creatorcontrib><creatorcontrib>Frantz, Robert P., MD</creatorcontrib><creatorcontrib>McGlothlin, Dana, MD</creatorcontrib><creatorcontrib>Horn, Evelyn M., MD</creatorcontrib><creatorcontrib>Benza, Raymond L., MD</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of heart and lung transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fang, James C., MD</au><au>DeMarco, Teresa, MD</au><au>Givertz, Michael M., MD</au><au>Borlaug, Barry A., MD</au><au>Lewis, Gregory D., MD</au><au>Rame, J. Eduardo, MD, Mphil</au><au>Gomberg-Maitland, Mardi, MD, MSc</au><au>Murali, Srinivas, MD</au><au>Frantz, Robert P., MD</au><au>McGlothlin, Dana, MD</au><au>Horn, Evelyn M., MD</au><au>Benza, Raymond L., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation</atitle><jtitle>The Journal of heart and lung transplantation</jtitle><addtitle>J Heart Lung Transplant</addtitle><date>2012-09-01</date><risdate>2012</risdate><volume>31</volume><issue>9</issue><spage>913</spage><epage>933</epage><pages>913-933</pages><issn>1053-2498</issn><eissn>1557-3117</eissn><abstract>Pulmonary hypertension associated with left heart disease is the most common form of pulmonary hypertension encountered in clinical practice today. Although frequently a target of therapy, its pathophysiology remains poorly understood and its treatment remains undefined. Pulmonary hypertension in the context of left heart disease is a marker of worse prognosis and disease severity, but whether its primary treatment is beneficial or harmful is unknown. An important step to the future study of this important clinical problem will be to standardize definitions across disciplines to facilitate an evidence base that is interpretable and applicable to clinical practice. In this current statement, we provide an extensive review and interpretation of the current available literature to guide current practice and future investigation. At the request of the Pulmonary Hypertension (PH) Council of the International Society for Heart and Lung Transplantation (ISHLT), a writing group was assembled and tasked to put forth this document as described above. The review process was facilitated through the peer review process of the Journal of Heart and Lung Transplantation and ultimately endorsed by the leadership of the ISHLT PH Council.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>22884380</pmid><doi>10.1016/j.healun.2012.06.002</doi><tpages>21</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1053-2498 |
| ispartof | The Journal of heart and lung transplantation, 2012-09, Vol.31 (9), p.913-933 |
| issn | 1053-2498 1557-3117 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1033453307 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Biological and medical sciences Cardiology. Vascular system Endothelin Receptor Antagonists Heart Diseases - complications heart failure heart transplant Heart-Assist Devices Humans Hypertension, Pulmonary - diagnosis Hypertension, Pulmonary - etiology Hypertension, Pulmonary - physiopathology Hypertension, Pulmonary - therapy left heart disease left ventricular assist device Medical sciences Mitral Valve Insufficiency - complications Mitral Valve Stenosis - complications Phosphodiesterase Inhibitors - therapeutic use Pneumology pulmonary hypertension Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases right heart failure Surgery Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the heart Vasodilator Agents - therapeutic use |
| title | World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T19%3A33%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=World%20Health%20Organization%20Pulmonary%20Hypertension%20Group%202:%20Pulmonary%20hypertension%20due%20to%20left%20heart%20disease%20in%20the%20adult%E2%80%94a%20summary%20statement%20from%20the%20Pulmonary%20Hypertension%20Council%20of%20the%20International%20Society%20for%20Heart%20and%20Lung%20Transplantation&rft.jtitle=The%20Journal%20of%20heart%20and%20lung%20transplantation&rft.au=Fang,%20James%20C.,%20MD&rft.date=2012-09-01&rft.volume=31&rft.issue=9&rft.spage=913&rft.epage=933&rft.pages=913-933&rft.issn=1053-2498&rft.eissn=1557-3117&rft_id=info:doi/10.1016/j.healun.2012.06.002&rft_dat=%3Cproquest_cross%3E1033453307%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1033453307&rft_id=info:pmid/22884380&rft_els_id=1_s2_0_S1053249812011242&rfr_iscdi=true |